alexa Perspectives Of Future Personalized Nanomedicine
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Farooq A Sheikh
Accepted Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.004
Cancer is not one but many diseases that annually afflict millions of people worldwide. Despite, the progress in understanding cancer, its treatment has remained essentially unchanged and the death rates of the disease remain as they were six decades ago. However, emerging genomic knowledge has revolutionized medicine and targeting the most appropriate patients with great precision may be a way of using molecular medicines in the most effective manner. Advanced nanomedicine has the potential to address one of the biggest problems in cancer therapy, how to get enough of the right drug to the right target. However, the lack of identified molecular biomarkers that could fully explain epigenetic changes and the heritability of complex tumors make it very difficult for target recognition and treatment. Notably, advanced high speed genetic screening and sequencing technologies, enables both oncologists as well as academic researchers to learn more about tumor environment, drug targets and drug carriers. Compelling evidence supports that by designing nanocarriers to exact specifications that carry drugs are expected to lead the most effective personalized treatment, essentially with fewer side effects. Perspectives of looking ahead at new targets and newer approaches to cancer therapy in the hope that they will have the greatest antitumor activity with the least toxicity to the patient than is seen with currently used medicines. The long-awaited era of personalized nanomedicine may be finally arriving with an exciting present and a promising future.
Farooq A Sheikh is working as a Professor and Research Chair, in the Avalon University School of Medicine, Curacao, Netherland Antilles. He obtained his PhD from the prestigious Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. From 2010-2012, he was working as a group leader in one of the largest research center of France, Faculty of de Medecine, National Centre for Scientific Research, Marseille and a Post doctoral Fellow in the Mayo Clinic, USA, from 2007-2009. In 2008, he was invited as a speaker in the Experimental Biology, San Diego, California. He has an experience of more than 13 years of teaching and research from various medical institutions of world repute.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version